Risperidone in elderly schizophrenic patients - An open-label trial

被引：29

作者：

Berman, I ^{[1
]}

Merson, A ^{[1
]}

RachovPavlov, J ^{[1
]}

Allan, E ^{[1
]}

Davidson, M ^{[1
]}

Losonczy, MF ^{[1
]}

机构：

[1] HARVARD UNIV,SCH MED,CAMBRIDGE,MA 02138

来源：

AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY | 1996年 / 4卷 / 02期

关键词：

D O I：

10.1097/00019442-199621420-00010

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

The authors assessed the safety and efficacy of risperidone in a group of elderly, patients with chronic schizophrenia and behavioral disturbances (N = 10). There were no clinically significant changes on physical examination. Also, schizophrenic symptoms and cognitive performance improved during risperidone administration. Patients showed a sufficient improvement in both areas to warrant a larger, double-blind study assessing the effects of risperidone on cognitive and psychiatric symptoms in elderly psychotic patients.

引用

页码：173 / 179

页数：7

共 21 条

[1]

[Anonymous], 1985, HALSTEAD REITAN NEUR

[2]

Benton AL., 1976, MULTILINGUAL APHASIA

[3] THE EFFICACY OF THE D2 AND 5-HT2 ANTAGONIST RISPERIDONE (R-64-766) IN THE TREATMENT OF CHRONIC PSYCHOSIS - AN OPEN DOSE-FINDING STUDY [J].